Several other equities research analysts have also recently commented on IPXL. Zacks Investment Research raised Impax Laboratories from a "hold" rating to a "buy" rating and set a $23.00 price target for the company in a research note on Monday, October 16th.
Original Article: Impax Laboratories (IPXL) Cut to "Sell" at BidaskClub
NEXT ARTICLE